Investigational drug · Phase 3
NTLA-2001
Also called: nexiguran ziclumeran
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "NTLA-2001"
First trial start
2023
Dec 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTLA-2001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuromuscular Disease
- Neuromuscular Diseases (NMD)
- Neurodegenerative Disease
- Neurodegenerative Disease, Hereditary
- Neurodegenerative Diseases
- Neuromuscular Diseases
- Nerve Disorders
- Nervous System Disease
- Nervous System Diseases
- Genetic Disease, Inborn
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NTLA-2001" as an intervention, largest first.
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)Pivotal-lookingRecruiting
Intellia TherapeuticsIndustry
NCT06128629 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Dec 2027
Drug: NTLA-2001; Placebo · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 138 sites in all
Intellia TherapeuticsIndustry
NCT04601051 · 72 participants · Start Nov 5, 2020 · Primary completion Sep 12, 2025
Drug: NTLA-2001 · For: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy; Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy; Wild-Type Transthyretin Cardiac Amyloidosis
Sites: Paris, France; Auckland, New Zealand; Umeå, Sweden · 4 sites in all
- A Phase 3 Study of NTLA-2001 in ATTRv-PNPivotal-lookingActive, not recruiting
Intellia TherapeuticsIndustry
NCT06672237 · 67 participants · Start Nov 22, 2024 · Primary completion Jul 2027
Drug: nexiguran ziclumeran; Normal Saline as Placebo · For: Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease and 17 more
Sites: Buenos Aires, Argentina; San Juan Bautista, Argentina; Campinas, Brazil · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Nanoparticle-Mediated Delivery of CRISPR/Cas9 Rnps Into Cells.
Rajeshwar V, Kumar KR, Kumar GR, et al. · Curr Gene Ther 2026
- Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future Perspectives.
Ide T, Yoshikawa M, Koike H · Neurol Ther 2026
- Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions.
Bains S, Atwal H, Sidhu A, et al. · Pharmaceuticals (Basel) 2026
- Current and emerging treatment options for transthyretin amyloid cardiomyopathy.
Vergaro G, Ferrari Chen YF, Ioannou A, et al. · Heart 2026
- Transthyretin amyloid cardiomyopathy: from cause to novel treatments.
Fontana M, Aimo A, Emdin M, et al. · Eur Heart J 2026
- Nanoparticle-enhanced CRISPR delivery: paving the path for in vivo tumor gene editing.
Khizar M, Aminpoor H, Zaib M, et al. · Ann Med Surg (Lond) 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.